PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Fallopian tube neoplasm

Drugs in development · updated 30 October 2026

Fallopian tube neoplasm: drugs in development

As of 30 October 2026 there are 141 active clinical trials (recruiting or ongoing, phases I–III) on 124 drugs for fallopian tube neoplasm. 55 are experimental, that is not yet approved in the United States.

141Active trials
55Experimental drugs
11Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
CediranibZemfirza®II–III4NCT02502266
IMNN-001III3NCT06915025
OregovomabIII3NCT04498117
TaxaneIII2NCT05281471
Torvutatug samrotecanIII2NCT07816666
BG-C9074III1NCT07811271
BL-M07D1III1NCT07545460
IBI354III1NCT06834672
Izalontamab brengitecanBL-B01D1, BMS-986507III1NCT06994195
JSKN003III1NCT06751485
Sacituzumab TirumotecanSKB264III1NCT06824467
AdavosertibAZD1775II3NCT02101775
UbamatamabI–II3NCT03564340
AnlotinibAL3818, AnrotinibII2NCT07489300
BerzosertibII2NCT02595892
FianlimabREGN3767I–II2NCT04590326
FluzoparibFuzuloparib, fluzopanibII2NCT06735326
IMGN151II2NCT07024784
IpatasertibII2NCT05564377
23ME-00610I–II1NCT05199272
ART0380I–II1NCT04657068
AVZO-021I–II1NCT05867251
BenmelstobartTQB2450II1NCT07489300
CeralasertibAZD6738II1NCT03579316
GotistobartONC-392II1NCT05446298
GTAEXS617I–II1NCT05985655
HS-20089II1NCT06014190
IparomlimabiparomilimabI–II1NCT06602063
MDNA11I–II1NCT05086692
PalacaparibAZD9574I–II1NCT05417594
PlixorafenibII1NCT05503797
RC48II1NCT06420973
REGN10597II1NCT06787612
REGN5668I–II1NCT04590326
SenaparibSepalna®II1NCT06617923
Trastuzumab RezetecanTrastuzumab RezatecanII1NCT07843303
TuvonralimabI–II1NCT06602063
UtideloneII1NCT07044349
VeliparibABT-888I–II1NCT01012817
VudalimabII1NCT05032040

Sorted by most advanced phase and number of active trials. Showing 40 of 55 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
PaclitaxelTaxol, PaxlitaxelII–III40NCT06161025
Bevacizumabavastin, MVASIII–III37NCT02839707
CarboplatinCarboplatine, ParaplatinIII36NCT07743164
OlaparibAZD2281, Lynparza®II–III17NCT02502266
GemcitabineGemcitabin, GemzarIII16NCT07743164
Pegylated liposomal doxorubicinLiposomal Doxorubicin, DOXILII–III14NCT02839707
PembrolizumabKEYTRUDA, MK-3475III12NCT05116189
TopotecanHycamtin®, Topotecan Hospira®II–III10NCT06161025
CisplatinCis Platinum, CisplatineIII7NCT05281471
Mirvetuximab SoravtansineIMGN853, Elahere®III6NCT05445778
Nab-paclitaxelAbraxane, Nab-placlitaxelIII6NCT05257408
NiraparibZejula®III5NCT06915025
Letrozoleoral FemaraIII4NCT04095364
NivolumabOpdivo, ONO-4538III4NCT03522246
DocetaxelTaxotere, Beizray®III3NCT05281471

Sorted by most advanced phase and number of active trials. Showing 15 of 69 drugs.

All 124 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005185 “Fallopian Tube Neoplasms”.

ItalianoFrançaisDeutsch